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The cloning of the melanocortin-1 receptor (MC1R) gene
from human melanocytes and the demonstration that
these cells respond to the melanocortins a-melanocyte
stimulating hormone (a-MSH) and adrenocorticotropic
hormone (ACTH) with increased proliferation and mel-
anogenesis have renewed the interest in investigation the
physiological role of these hormones in regulating human
pigmentation. a-Melanocyte stimulating hormone and
ACTH are both synthesized in the human epidermis, and
their synthesis is upregulated by exposure to ultraviolet
radiation (UVR). Activation of the MC1R by ligand
binding results in stimulation of cAMP formation, which
is a principal mechanism for inducing melanogenesis.
The increase in cAMP is required for the pigmentary
response of human melanocytes to UVR, and for allowing
CUTANEOUS PIGMENTATION, PHOTOPROTECTION,
AND SKIN CANCER RISK
Exposure to ultraviolet rays (UVR) from solar radiation is known be
the main etiologic factor for skin cancers (Epstein, 1983; Sober
et al, 1991). Chronic exposure to the sun is known to result in
photocarcinogenesis and photoaging (Epstein, 1983; Sober et al, 1991).
The incidence of skin cancer is increasing at an alarming rate, and is
accentuated by the depletion of the ozone layer that limits the
penetration of UVR through the earth’s atmosphere (Redman, 1987).
The risk for skin cancer is much higher in individuals with fair skin
and blue eyes, who have a poor tanning ability (skin type I or II
individuals) than in individuals with dark skin who tan efficiently when
exposed to UVR (skin types III–VI) (Epstein, 1983; Sober et al, 1991;
Pathak et al, 1980; Kaidbey et al, 1979). The presence of high melanin
content in the latter skin types is known to limit the penetration of
UVR through the epidermal layers, and thus reduce the photodamaging
effects of sun exposure (Kaidbey et al, 1979). Melanin is synthesized
and packaged within melanosomes in epidermal melanocytes, and
melanosomes from each melanocyte are then transferred to the
surrounding keratinocytes (Pathak et al, 1980). The rate of melanin
synthesis by melanocytes and the rate of delivery of melanosomes to
keratinocytes are two important determinants of constitutive skin
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them to overcome the UVR-induced G1 arrest. Treat-
ment of human melanocytes with a-MSH increases
eumelanin synthesis, an effect that is expected to enhance
photoprotection of the skin. Population studies have
revealed more than 20 allelic variants of the MC1R gene.
Some of these variants are overexpressed in individuals
with skin type I or II, red hair, and poor tanning ability.
Future studies will aim at further exploration of the role
of these variants in MC1R function, and in determining
constitutive human pigmentation, the response to sun
exposure, and possibly the susceptibility to skin cancer.
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color. Interest in investigating the regulation of human cutaneous
pigmentation stems primarily from the importance of melanin in
photoprotection (Morison, 1985; Menon and Haberman, 1977). The
photoprotective effect of melanin has been attributed to its ability to
filter and attenuate solar radiation by scattering, as well as by absorption
and dissipation as heat (Pathak et al, 1980, 1995; Kaidbey et al, 1979).
Microscopic examination of different skin types revealed that in skin
type I, melanized melanosomes are degraded in the lower epidermal
layers, while in dark skin, melanosomes remain intact even in the
horny layer (Pathak et al, 1971). The presence of melanosomes in
the epidermis of dark skinned individuals has recently been shown to
confer photoprotection, because melanosomes form supranuclear caps
that reduce the extent of DNA photoproducts by limiting the amount
of UVR that reach nuclear DNA (Kobayashi et al, 1998).
EUMELANIN VERSUS PHEOMELANIN IN HUMANS
Human epidermal melanocytes synthesize both eumelanin and
pheomelanin. The presence of cysteine in pheomelanin accounts for
its reddish-yellowish color that distinguishes it from the dark brown
eumelanin (Prota et al, 1967, 1998). In mouse hair follicles, eumelanin
synthesis is associated with increased expression of the melanogenic
enzymes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2,
whereas pheomelanin synthesis is associated with a reduction in
tyrosinase and absence of TRP-1, TRP-2, and P protein (Kobayashi
et al, 1995; Lamoreux et al, 1995). The ratio of eumelanin to
pheomelanin differs dramatically in different skin phenotypes, being
highest in skin types V and VI, and lowest in skin types I and II (Hunt
et al, 1995a). Not only total melanin content (Kaidbey et al, 1979),
30 SUZUKI ET AL JID SYMPOSIUM PROCEEDINGS
but the ratio of eumelanin to pheomelanin seem to dictate the extent
of photoprotection conferred by total melanin content in the epidermis.
Earlier studies showed that pheomelanin was more photolabile than
eumelanin (Menon et al, 1985). Irradiation of pheomelanin was found
to generate considerable amounts of superoxide, while irradiation of
eumelanin did not. In fact, eumelanin behaved as a pseudo-dismutase,
thus reducing cellular oxidative stress. The addition of irradiated
pheomelanin to cells resulted in their lysis, a response thought to be
caused by the generation of hydrogen peroxide from superoxide, and
the possible formation of singlet oxygen and hydroxyl radicals (Menon
et al, 1983). Another factor that contributed to cell lysis is membrane
lipid peroxidation and the oxidation of cysteine in membrane proteins
that caused alteration of their structure (Chedekel and Zeise, 1988).
In mammalian melanocytes, the synthesis of eumelanin is stimulated
by α-melanocyte stimulating hormone (α-MSH) (Geschwind et al,
1972; Hunt et al, 1995b). Treatment of human melanocytes with
α-MSH stimulates the synthesis of eumelanin without significantly
altering total melanin, thus resulting in an increased eumelanin to
pheomelanin ratio. Because UVR stimulates the synthesis of α-MSH
and the related hormone adrenocorticotropic hormone (ACTH) in
epidermal melanocytes and keratinocytes, it is expected that UV
exposure will increase eumelanin formation (Schauer et al, 1994;
Chakraborty et al, 1996).
In human epidermal melanocytes, as well as in mouse follicular
melanocytes, eumelanin synthesis is stimulated by the activation of the
melanocortin 1 receptor (MC1R), the receptor for α-MSH that is
coded for by the extension locus (Tamate and Takeuchi, 1984; Mountjoy
et al, 1992; Robbins et al, 1993; Hunt et al, 1995b). In the mouse, the
switch between eumelanin and pheomelanin synthesis in follicular
melanocytes is primarily regulated by the extension locus and the agouti
locus that codes for a soluble factor, agouti signaling protein (ASP)
(Tamate and Takeuchi, 1984; Silvers, 1958, 1979; Yen et al, 1994).
The availability and processing of proopiomelanocortin (POMC), the
precursor for all melanocortins, is also important for stimulation of
eumelanin formation (Eipper and Mains, 1980; Wakamatsu et al, 1997).
Recently, two mutations in the POMC gene were identified in two
unrelated children. These mutations resulted in red hair, as well as
obesity and adrenal insufficiency associated with deficiency of POMC
products, particularly α-MSH and ACTH (Krude et al, 1998). In the
mouse, loss of function mutations at the extension locus result in a
yellow coat color due to inability of follicular melanocytes to respond
to α-MSH with eumelanin synthesis (Tamate and Takeuchi, 1984;
Robbins et al, 1993). Also, mutations at the agouti locus that result in
excessive and ectopic synthesis of ASP result in yellow coat color and
obesity, due to competitive inhibition of α-MSH binding to the
MC1R and MC4R (the receptor for α-MSH in the hypothalamus),
respectively, by ASP (Lu et al, 1994; Yang et al, 1997; Ollmann et al,
1998). Inhibition of MC1R activity by ASP results in blocking of
eumelanin production and stimulation of pheomelanin synthesis. We
have shown that human melanocytes respond to α-MSH and ACTH
with stimulation of melanin formation and increased proliferation
(Abdel-Malek et al, 1995; Suzuki et al, 1996). Recently, we demon-
strated that human melanocytes respond to purified recombinant human
or mouse ASP with a reduction in basal tyrosinase activity and complete
abrogation of the mitogenic and melanogenic effects of α-MSH,
changes known to be associated with induction of pheomelanin
synthesis (Kobayashi et al, 1995; Suzuki et al, 1997). As in the case of
mouse follicular melanocytes, ASP acted as a competitive inhibitor of
α-MSH binding to the human MC1R.
THE PHYSIOLOGIC EFFECTS OF α-MSH
α-Melanocyte stimulating hormone has been known for decades to
be the physiologic stimulator of integumental pigmentation of many
vertebrate species, including fish, reptiles, amphibians, and mammals
(Sawyer et al, 1983; Sherbrooke et al, 1988). In animals that undergo
rapid color change α-MSH stimulates the dispersion of preexisting
melanin-containing melanosomes, resulting in skin darkening. In the
mouse, the most widely used animal model to study the regulation
of mammalian pigmentation, α-MSH induces de novo synthesis of
eumelanin within follicular melanocytes (Geschwind et al, 1972; Levine
et al, 1987). Gain of function mutations in the α-MSH receptor as in
the homozygous tobacco mouse have been characterized and shown
to result in increased ability to synthesize eumelanin, whereas loss of
function mutations result in yellow coat color, due to the synthesis of
pheomelanin (Tamate and Takeuchi, 1984; Robbins et al, 1993).
α-MSH belongs to the family of melanocortins, which include β-,
γ-MSH, and ACTH (Smith et al, 1998). All of these bioactive
peptides, together with β-lipotropic hormone and β-endorphin, are
derived from a large precursor peptide, POMC (Rubinstein et al,
1978; Liotta et al, 1980). This peptide is classically known to be
synthesized in the pituitary gland and to be processed by two main
enzymes, prohormone convertase (PC) 1 and PC2 (Bloomquist
et al, 1991; Lindberg, 1991). The former enzyme results in the
formation of full length ACTH[1–39], and the latter cleaves ACTH
into α-MSH[1–13]. The entire 13 amino acid sequence that makes
up the structure of α-MSH is included within the structure of
ACTH. It is now recognized that POMC is synthesized and
differentially processed in many different tissues and organs,
including various brain regions, the hypothalamus, placenta, gonads,
gastrointestinal tract, and the skin (O’Donohue and Dorsa, 1982;
Can et al, 1998). The presence of α-MSH-like peptides in human
skin was reported many years ago (Thody et al, 1983). Recently,
this was substantiated by the demonstration that cultured human
epidermal keratinocytes and melanocytes synthesize α-MSH and
ACTH (Schauer et al, 1994; Chakraborty et al, 1996). The presence
of POMC as well as the enzyme PC1 in human epidermis in situ
was also demonstrated (Wakamatsu et al, 1997). This suggests that
melanocortins are potential paracrine/autocrine factors that regulate
specific epidermal functions in human skin.
In addition to its best-described role as a regulator of skin pigmenta-
tion, α-MSH and related hormones serve many other functions. In
several animal models α-MSH has been shown to be a potent inhibitor
of the pyrogenic effects of interleukin-1 (IL-1) (Murphy et al, 1983;
Robertson et al, 1988). This initial observation led to many studies
describing the systemic, as well as the cutaneous anti-inflammatory
effects of α-MSH, which include inhibition of antibody formation by
B-lymphocytes, and suppression of contact hypersensitivity (Rheins
et al, 1989; Luger et al, 1998). The immunosuppressive effects of
α-MSH in the skin are mediated, at least in part, by stimulation of
IL-10 synthesis, and by inhibition of the synthesis of IL-1, IL-6, and
tumor necrosis factor-α (Luger et al, 1998). Other effects of α-MSH
and related peptides include trophic effects on the adrenals during fetal
development, stimulation of neuroneal regeneration following nerve
injury and increased neurite formation, regulation of gonadal function,
participation in the regulation of feeding behavior, and stimulation of
memory and learning (Beckwith et al, 1977; Pigache and Rigter, 1981;
Silman et al, 1981; Verhaagen et al, 1986; Seeley et al, 1997).
THE MELANOCORTIN RECEPTORS
The pleiotropic effects of α-MSH are mediated by binding to one of
five melanocortin receptors (MCR) that are expressed by different
types of target cells (Mountjoy et al, 1992; Chhajlani et al, 1993;
Roselli-Rehfuss et al, 1993; Gantz et al, 1993a, b; Labbe´ et al, 1994).
These receptors have been cloned and found to be coded for by five
distinct genes. The five MCR represent a distinct family of G-protein
coupled receptors with seven transmembrane domains. Binding of
ligand to these receptors activates adenylate cyclase and stimulates
cAMP formation. The MCR differ in their tissue distribution and in
their relative affinities for the various melanocortin peptides. The first
of these receptors, the MC1R, was cloned from mouse Cloudman
melanoma cells and normal human melanocytes (Mountjoy et al, 1992).
The MC2R was cloned from the adrenal medulla (Chhajlani et al,
1993); this receptor is the ACTH receptor, and among the melanocortin
peptides, it recognizes ACTH with the highest affinity. The MC3,
MC4, and MC5R were subsequently cloned (Roselli-Rehfuss et al,
1993; Gantz et al, 1993a, b; Labbe´ et al, 1994). The MC3R seems to
be selective for γ-MSH, and is expressed mainly in the hypothalamus,
the placenta, and gastrointestinal tract. The MC4R is expressed widely
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in the brain, and participates in the regulation of food intake. Disruption
of function of the MC4R in the mouse results in obesity (Huszar et al,
1997). The MC5R was recently shown to be important for the
regulation of exocrine gland function, and disruption of this receptor
in the mouse results in defects in water repulsion and thermoregulation,
due to reduced lipid production by sebaceous glands (Chen et al, 1997).
MELANOCORTINS, MC1R, AND HUMAN CUTANEOUS
PIGMENTATION
The physiologic role of α-MSH in the regulation of integumental
pigmentation of many vertebrate species has been recognized for
many years; however, its role in the regulation of human cutaneous
pigmentation remained controversial and is still not very well under-
stood. Decades ago, Lerner and McGuire demonstrated that injection
of human volunteers with high concentrations of α- and β-MSH, or
with α-MSH and ACTH, resulted in skin darkening (Lerner and
McGuire, 1961, 1964). Years later, Levine et al reported that injection
of human subjects with a superpotent analog of α-MSH, namely [Nle4,
D-Phe7] α-MSH, increased skin pigmentation, especially in anatomical
sites that are habitually exposed to the sun (Levine et al, 1991). These
reports suggested that melanocortins induce human skin darkening,
but did not provide a solid evidence for a direct response of human
melanocytes to these hormones. Some in vitro studies on cultured
human melanocytes failed to demonstrate any pigmentary effect of
α-MSH, and based on this, it was inferred that these cells do not
express receptors for this hormone (Halaban et al, 1993). Those results
were challenged by the cloning of the MC1R and the demonstration
that this receptor is expressed on normal human epidermal melanocytes
(Donatien et al, 1992; Mountjoy et al, 1992). The pharmacologic
characterization of the human MC1R revealed that it is more sensitive
to α-MSH and to ACTH than the mouse MC1R (Mountjoy,
1994). Subsequently, it was shown that treatment of cultured human
melanocytes with α-MSH increases melanogenesis. Another report,
however, concluded that α-MSH stimulates human melanocyte
proliferation, but has no effect on melanogenesis (De Luca et al, 1993).
We have reported that α-MSH is both mitogenic and melanogenic
for human melanocytes in vitro (Abdel-Malek et al, 1995). Moreover,
we showed that these cells respond equally well to α-MSH and ACTH.
In a later report, we demonstrated that the MC1R expressed on human
epidermal melanocytes binds α-MSH and ACTH with the same
affinity, has a lower affinity for β-MSH, and least affinity for γ-MSH
(Suzuki et al, 1996). The differential ability of the above four melanocor-
tins to bind and activate the MC1R on human melanocytes was
corroborated by their respective stimulatory effects on tyrosinase
activity, and hence melanogenesis, as well as proliferation (Suzuki
et al, 1996).
The above described in vitro studies were the first to demonstrate a
direct effect of melanocortins on normal human melanocytes, suggesting
a role for these hormones in the regulation of human cutaneous
pigmentation. Subsequent studies revealed that activation of the MC1R
on human epidermal melanocytes stimulated eumelanin formation
(Hunt et al, 1995b). In this respect, the human MC1R is homologous
to its mouse counterpart that is known to induce eumelanin synthesis
in follicular melanocytes. Epidermal human melanocytes are known
to express a low number (µ1000 binding sites per cell) of MC1R
(Donatien et al, 1992). As mentioned earlier, the human MC1R is
more sensitive to α-MSH and ACTH than its mouse counterpart,
which has led to the conclusion that the human MC1R has evolved
to be supersensitive to melanotropins, and that ACTH might play a
physiologic role in regulating human pigmentation (Mountjoy, 1994;
Suzuki et al, 1996). We have found that activation of human MC1R
by ligand binding results in prolonged increase (for at least 24 h) in
the synthesis of the second messenger cAMP (Suzuki et al, 1996). In
contrast, in mouse melanoma cells, stimulation of cAMP formation by
α-MSH treatment persisted for less than 2 h (Wong et al, 1974). We
have found that the human MC1R mRNA level is upregulated by
brief treatment with either α-MSH or ACTH (Suzuki et al, 1996).
We also found that the MC1R does not undergo desensitization, as
evidenced by the ability of human melanocytes to respond to continued
and prolonged treatment with these hormones. These properties of
the human MC1R might compensate for the low level of expression
of the MC1R on human melanocytes and explain the sensitivity of
these cells to α-MSH and ACTH.
We have found that, unlike human melanocytes, cultured human
keratinocytes lack the expression of the MC1R (unpublished results).
Using northern blot analysis, we could detect MC1R mRNA in
melanocytes using 5 µg total RNA. In the same experiments, we
could not detect any MC1R mRNA in keratinocytes, even when
using a 10-fold higher amount of total RNA. Also, by receptor
binding assays, we could not find any specific binding of α-MSH to
keratinocytes. Furthermore, cAMP radioimmunoassays did not reveal
any increase in cAMP levels in keratinocytes following treatment with
α-MSH, γ-MSH, or ACTH. The results of these various assays indicate
that human keratinocytes differ from human melanocytes in that they
do not constitutively express functional MCR.
It has been reported that human endothelial cells, antigen-presenting
cells, and macrophages express MC1R, as determined by RT-PCR
analysis, and immunostaining using an antibody for MC1R (Hartmeyer
et al, 1997; Bhardwaj et al, 1997). These receptors were found to be
activated by subpicomolar concentrations of α-MSH, whereas the
minimal effective dose of α-MSH that is required for activation of
the MC1R expressed on melanocytes is 0.1 nM. Hence, it is important
to pharmacologically characterize the putative MC1R on cells other
than melanocytes, using competitive binding assays and cAMP radio-
immunoassays.
The involvement of melanocortins in the UV-induced melanogenic
response has long been proposed. Exposure of mouse Cloudman
melanoma cells to UVR has been shown to increase α-MSH binding
and to upregulate the expression of the α-MSH receptor (Pawelek
et al, 1992; Chakraborty et al, 1995). Irradiation of brown guinea pigs
with UVR resulted in increased pigmentation, an effect that was
significantly augmented by the topical application of α-MSH to
the irradiated sites (Bolognia et al, 1989). Evidence for a role of
melanocortins in the responses of human melanocytes to UVR was
suggested by the observations that UVR increases the serum levels of
α-MSH, and stimulates the synthesis of α-MSH and ACTH by human
keratinocytes and melanocytes (Altmeyer et al, 1986; Schauer et al,
1994; Chakraborty et al, 1996). We have been investigating the possible
role of α-MSH in the UV-induced response of normal human
melanocytes (Im et al, 1998). We found that in the absence of this
hormone or any other agent that activates the cAMP pathway, human
melanocytes respond to UVR with a decrease, rather than an increase,
in tyrosinase activity, and with a profound reduction in the amount of
tyrosinase. The melanogenic effect of UVR was only obvious when
UV-irradiated melanocytes were treated with α-MSH or any other
cAMP inducer. These results underscore the importance of the cAMP
pathway in stimulating melanogenesis. Among the known regulators
of human melanocytes, α-MSH and ACTH are the best known to
activate the cAMP signaling pathway. Therefore, we propose that these
hormones are pivotal for the melanogenic response to UVR.
We have reported that a single irradiation of human melanocytes
with UVR resulted in their arrest in G1 (Barker et al, 1995). We
also found that UVR resulted in a dose-dependent increase in cell
death. Treatment of melanocytes with α-MSH immediately after UV
irradiation resulted in their partial recovery from G1 arrest, but did
not reduce the extent of cell killing (Im et al, 1998). At sublethal
doses of UVR, we found that treatment of irradiated melanocytes with
α-MSH significantly enhanced their proliferative rate, and completely
reversed the growth inhibitory effect of UVR (unpublished results).
We conclude, based on these results, that the increase in epidermal
melanocyte activity and number that is observed in sun-exposed skin
in situ, can be attributed at least partially to α-MSH and ACTH.
Irradiation of melanocytes in the absence of α-MSH with a lethal dose
of UVBR resulted in a prolonged increase in the accumulation of the
tumor suppressor protein p53, enhanced expression of the cyclin-cdk
inhibitor p21, and reduction of the level of the apoptotic inhibitor
Bcl2 (Garcia et al, 1992; Ullrich et al, 1992; El-Deiry et al, 1993; Reed,
1994; Im et al, 1998). Because p53 is a cell cycle checkpoint,
accumulation of p53 and the resulting induction of p21 are expected
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to arrest cells in G1 (Ullrich et al, 1992; El-Deiry et al, 1993; Harper
et al, 1993). Treatment of melanocytes immediately after UV irradiation
with α-MSH did not reverse these effects, but induced melanocyte
proliferation despite the high levels of p53 and p21 (Im et al, 1998).
These findings suggest that α-MSH induces the proliferation of
irradiated melanocytes by activating a p53 independent pathway. The
observation that α-MSH stimulated the proliferation of UV-irradiated
melanocytes but did not reduce the lethal effects of UVR indicates
that this hormone is mainly a mitogen, and not a survival factor for
these cells.
We hypothesize that the response of human melanocytes to UVR
is mediated to a large extent by a network of paracrine factors that are
induced in the epidermis upon UV exposure. These factors include
interleukin-1, α-MSH, ACTH, endothelin-1, and basic fibroblast
growth factor (Kupper et al, 1987; Halaban et al, 1988; Imokawa et al,
1992; Schauer et al, 1994; Chakraborty et al, 1996). Interleukin-1 is
known to be a primary cytokine, and to induce the synthesis of
endothelin-1 by keratinocytes, and of α-MSH and ACTH by ker-
atinocytes and melanocytes (Chakraborty et al, 1996; Imokawa et al,
1992). After UV exposure, keratinocyte-derived factors regulate the
proliferation and melanization of melanocytes, whereas the melanocyte
protects the keratinocytes from photodamage by increasing the rate of
synthesis and transfer of eumelanin containing melanosomes. In our
studies on the regulation of the MC1R, we found that in the absence
of mitogens, UVR resulted in a dose-dependent reduction in the
MC1R mRNA level in epidermal melanocytes (unpublished results).
Treatment with α-MSH immediately after UV exposure resulted in
reversing the inhibitory effect of UVR and in upregulating the mRNA
level for MC1R. Interestingly, we found that the MC1R mRNA level
is upregulated by endothelin-1 (Tada et al, 1998) and basic fibroblast
growth factors (unpublished results), two keratinocyte-derived factors
that act as paracrine mitogens for human melanocytes. The synthesis
of these two factors by keratinocytes is stimulated by UVR (Imokawa
et al, 1992; Halaban et al, 1988). Based on this, we propose that
activation of MC1R expression is central to the paracrine regulation
of human melanocytes and their response to UVR, and is an important
determinant of the extent of photoprotection in the epidermis.
MC1R ALLELIC VARIANTS
There is increasing evidence that mutations in the MC1R gene and
low eumelanin to pheomelanin ratio in the epidermis are associated
with poor tanning ability and increased risk for skin cancer (Valverde
et al, 1995). In the populations so far studied, variants of the MC1R
gene have been identified and found to be expressed in ver 80% of
individuals with red (pheomelanogenic) hair (Valverde et al, 1995).
These individuals have skin type I or II phenotype, tend to burn easily,
and tan poorly when exposed to the sun. Most of the mutations so far
identified are clustered in a region of 42 amino acids spanning the
second transmembrane domain of the MC1R. Recently, eight MC1R
variants were identified in an Irish population. Three of these variants,
namely Arg151Cys, Arg160Trp, and Asp294His, were significantly
over represented in individuals with red hair (Smith et al, 1998). The
presence of any variant together with Arg151Cys was strongly associated
with individuals who have freckles and a poor tanning response. The
presence of Asp294His variant was also common in red headed Dutch
individuals. The possible association of MC1R variants with melanoma
has been investigated by comparing the frequency of variants in the
second and seventh transmembrane domains in 43 melanoma cases and
44 controls (Valverde et al, 1996). Forty-six per cent of the melanoma
patients were carriers of variant alleles, compared with only 18 per
cent in the controls. The Asp84Glu variant was detected in 23% of
melanoma tumors but not in any of the controls. The possible
association between MC1R variants and the risk for melanoma needs
to be further investigated, because some variants might prove useful as
markers to predict the risk for this disease.
About 20 allelic variants of the human MC1R have been identified
so far. Whether or not these variants impair the function of the MC1R
has not been fully investigated. The consequence of only two point
mutations, Arg151Cys and Val 92Met, on the function of the MC1R has
been determined. Expression of the Arg151Cys variant in heterologous
cells revealed that this mutant receptor had a normal binding affinity
for α-MSH, but was totally deficient in activating adenylate cyclase,
as monitored by lack of stimulation of cAMP formation (Fra¨ndberg
et al, 1998). It was reported that the Val92Met substitution generated
a NSP1 restriction site and unique restriction fragments of 359 and
724 bp. This mutation was found to have no significant effect on the
binding or signaling of the MC1R (Koppula et al, 1997); however, in
another study, this variant receptor was reported to have a reduced
binding affinity for α-MSH (Xu et al, 1996). We and others (Jonathan
Rees, personal communication) did not find a correlation between
Val92Met variant expression and hair color, skin type, and loss of
MC1R function. Therefore, we presume that this variant might have
a minimal effect that cannot be detected in the human populations
that have been studied so far.
To gain a better understanding of the significance of the MC1R
gene mutations for the MC1R function and eumelanin formation, we
compared the responses of various epidermal melanocyte cultures to
α-MSH and the genetic sequences of their MC1R gene. We conducted
dose–response experiments to determine the stimulatory effects of α-
MSH on cAMP formation, tyrosinase activity, and proliferation. We
tested five melanocyte cultures, each derived from a single skin type
V or VI donor, and found that the minimal effective dose of α-MSH
in all of the above assays was 0.1 nM. The cAMP data obtained from
these experiments were consistent with the results obtained using the
cloned wild-type MC1R expressed in heterologous cells. In five
melanocyte cultures that were established from skin type I or II donors,
one culture had a diminished response to α-MSH and demonstrated
a shift to the right (by one or two logs) in the dose–response curves
in all three assays. We are pursuing the genetic analysis of the MC1R
to determine the cause for the loss of function of the MC1R in these
melanocytes. Binding assays will be carried out in order to determine
whether or not the affinity of the MC1R for its ligands is reduced.
The response of melanocytes harboring mutated MC1R to UVR is
also being investigated, in order to determine the influence of the
MC1R variants on the extent of DNA damage in melanocytes.
SUMMARY
The demonstration that human epidermal melanocytes express func-
tional MC1R and respond to α-MSH and ACTH with increased
proliferation and melanogenesis, has put to rest a long lasting controversy
about the role of α-MSH in the regulation of human pigmentation.
Recent genetic studies clearly indicate that normal expression of the
MC1R and its ligands is essential for the synthesis of eumelanin.
Assuming that eumelanin is superior to pheomelanin in its photo-
protective properties suggests that melanotropins are likely to play an
important role in photoprotection of the skin against sun-induced
DNA damage. This is supported by the association between the MC1R
variants and poor tanning ability, and possibly melanoma formation.
Allelic variants of the MC1R have been identified and found to be
strongly associated with the red hair phenotype. The ramifications of
these variants on the function of the MC1R need to be rigorously
evaluated.
Supported in part by Grants R01 ES06882 (NIH), R01 ES-09110 (NIH), the
Dermatology Foundation, the Avon Products Skin Research grant, and Ohio Cancer
Research Associates grant (ZAM)
REFERENCES
Abdel-Malek Z, Swope VB, Suzuki I, et al: Mitogenic and melanogenic stimulation of
normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA
92:1789–1793, 1995
Altmeyer P, Sto¨hr L, Holzmann H: Seasonal rhythm of the plasma level of alpha-melanocyte
stimulating hormone. J Invest Dermatol 86:454–456, 1986
Barker D, Dixon K, Medrano EE, et al: Comparison of the responses of human melanocytes
with different melanin contents to ultraviolet B irradiation. Cancer Res 55:4041–
4046, 1995
Beckwith BE, Sandman CA, Hotherstall D, Kastin AJ: Influence of neonatal injections of
α-MSH on learning, memory and attention in rats. Physiol Behav 18:63–71, 1977
VOL. 4, NO. 1 SEPTEMBER 1999 MC1R AND UVR-INDUCED PIGMENTATION 33
Bhardwaj RS, Becher E, Mahnke K, Hartmeyer M, Schwarz T, Scholzen T, Luger TA:
Evidence for the differential expression of the functional alpha melanocyte stimulating
hormone receptor MC-1 on human monocytes. J Immunol 158:3378–3384, 1997
Bloomquist BT, Eipper BA, Mains RE: Prohormone-converting enzymes: regulation and
evaluation of function using antisense RNA. Mol Endocrinol 5:2014–2024, 1991
Bolognia J, Murray M, Pawelek J: UVB-induced melanogenesis may be mediated through
the MSH-receptor system. J Invest Dermatol 92:651–656, 1989
Can G, Abdel-Malek Z, Porter-Gill PA, et al: Identification and sequencing of a putative
variant of proopiomelanocortin in human epidermis and epidermal cells in culture.
J Invest Dermatol 111:485–491, 1998
Chakraborty A, Slominski A, Erinak G, Hwang J, Pawelek J: Ultraviolet B and melanocyte
stimulating hormone (MSH) stimulate mRNA production for α-MSH receptors
and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed
keratinocytes. J Invest Dermatol 105:655–659, 1995
Chakraborty AK, Funasaka Y, Slominski A, Ermak G, Hwang J, Pawelek JM, Ichihashi
M: Production and release of proopiomelanocortin (POMC) derived peptides by
human melanocytes and keratinocytes in culture: regulation by ultraviolet B. Biochim
Biophys Acta 1313:130–138, 1996
Chedekel MR, Zeise L: Sunlight, melanogenesis and radicals in the skin. Lipids 23:587–
591, 1988
Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, Cone RD: Exocrine gland
dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of
exocrine gland function by melanocortin peptides. Cell 91:789–798, 1997
Chhajlani V, Muceniece R, Wikberg JES: Molecular cloning of a novel human melanocortin
receptor. Biochem Biophys Res Commun 195:866–873, 1993
De Luca M, Siegrist W, Bondanza S, Mathor M, Cancedda R, Eberle AN: (Melanocyte
stimulating hormone (MSH) stimulates normal human melanocyte growth by binding
to high-affinity receptors. J Cell Sci 105:1079–1084, 1993
Donatien PD, Hunt G, Pieron C, Lunec J, Taı¨eb A, Thody AJ: The expression of
functional MSH receptors on cultured human melanocytes. Arch Dermatol Res
284:424–426, 1992
Eipper BA, Mains RE: Structure and biosynthesis of pro-adrenocorticotropin/endorphin
and related peptides. Endocr Rev 1:1–27, 1980
El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor
suppression. Cell 75:817–825, 1993
Epstein JH: Photocarcinogenesis, skin cancer and aging. J Am Acad Dermatol 9:487–
502, 1983
Fra¨ndberg P-A, Doufexis M, Kapas S, Chhajlani V: Human pigmentation phenotype: a
point mutation generates nonfunctional MSH receptor. Biochem Biophys Res Commun
245:490–492, 1998
Gantz I, Konda Y, Tashiro T, et al: Molecular cloning of a novel melanocortin receptor. J
Biol Chem 268:8246–8250, 1993a
Gantz I, Miwa H, Konda Y, et al: Molecular cloning, expression, and gene localization of
a fourth melanocortin receptor. J Biol Chem 268:15174–15179, 1993b
Garcia I, Martinou I, Tsujimoto Y, Martinou J-C: Prevention of programmed cell death
of sympathetic neurons by the bcl-2 proto-oncogene. Science 258:302–304, 1992
Geschwind RA, Huseby II, Nishioka R: The effect of melanocyte-stimulating hormone
on coat color in the mouse. Rec Prog Hormone Res 28:91–130, 1972
Halaban R, Langdon R, Birchall N, et al: Basic fibroblast growth factor from human
keratinocytes is a natural mitogen for melanocytes. J Cell Biol 107:1611–1619, 1988
Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J: Pigmentation and proliferation of
human melanocytes and the effects of melanocyte-stimulating hormone and
ultraviolet B light. Ann N Y Acad Sci 680:290–301, 1993
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting
protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–
816, 1993
Hartmeyer M, Scholzen T, Becher E, Bhardwaj S, Schwarz T, Luger.TA: Human dermal
microvascular endothelial cells (HMEC-1) express the melanocortin receptor type
1 and produce increased levels of IL-8 upon stimulation with αMSH. J Immunol
159:1930–1937, 1997
Hunt G, Kyne S, Ito S, Wakamatsu K, Todd C, Thody AJ: Eumelanin and pheomelanin
contents of human epidermis and cultured melanocytes. Pigment Cell Res 8:202–
208, 1995a
Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ: Nle4DPhe7 α-Melanocyte-stimulating
hormone increases the eumelanin: Phaeomelanin ratio in cultured human
melanocytes. J Invest Dermatol 104:83–85, 1995b
Huszar D, Lynch CA, Fairchild-Huntress V, et al: Targeted disruption of the melanocortin-
4 receptor results in obesity in mice. Cell 88:131–141, 1997
Im S, Moro O, Peng F, et al: Activation of the cAMP pathway by (-melanotropin mediates
the response of human melanocytes to UVB light. Cancer Res 58:47–54, 1998
Imokawa G, Yada Y, Miyagishi M: Endothelins secreted from human keratinocytes are
intrinsic mitogens for human melanocytes. J Biol Chem 267:24675–24680, 1992
Kaidbey KH, Poh Agin P, Sayre RM, Kligman AM: Photoprotection by melanin – a
comparison of black and Caucasian skin. J Am Acad Dermatol 1:249–260, 1979
Kobayashi T, Vieira WD, Potterf B, Sakai C, Imokawa G, Hearing VJ: Modulation of
melanogenic protein expression during the switch from eu- to pheomelanogenesis.
J Cell Sci 108:2301–2309, 1995
Kobayashi N, Nakagawa A, Muramatsu T, et al: Supranuclear melanin caps reduce
ultraviolet induced DNA photoproducts in human epidermis. J Invest Dermatol
110:806–810, 1998
Koppula SV, Robbins LS, Lu D, Baack E, White CR, Swanson NA, Jr, Cone RD:
Identification of common polymorphisms in the coding sequence of the human
MSH receptor (MC1R) with possible biological effects. Hum Mutat 9:30–36, 1997
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gru¨ters A: Severe early-onset
obesity, adrenal insufficiency and red hair pigmentaiton caused by POMC mutations
in humans. Nat Genet 19:155–157, 1998
Kupper TS, Chua AO, Flood P, McGuire J, Gubler U: Interleukin 1 gene expression in
cultured human keratinocytes is augmented by ultraviolet irradiation. J Clin Invest
80:430–436, 1987
Labbe´ O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M: Molecular cloning of a
mouse melanocortin 5 receptor gene widely expressed in peripheral tissues.
Biochemistry 33:4543–4549, 1994
Lamoreux ML, Zhou B-K, Rosemblat S, Orlow SJ: The pinkeyed-dilution protein and
the eumelanin/pheomelanin switch: In support of a unifying hypothesis. Pigment
Cell Res 8:263–270, 1995
Lerner AB, McGuire JS: Effect of alpha- and beta-melanocyte stimulating hormones on
the skin colour of man. Nature 189:176–179, 1961
Lerner AB, McGuire JS: Melanocyte-stimulating hormone and adrenocorticotrophic
hormone. Their relation to pigmentation. N Engl J Med 270:539–546, 1964
Levine N, Lemus-Wilson AL, Wood SH, Abdel-Malek ZA, Al-Obeidi F, Hruby VJ,
Hadley ME: Stimulation of follicular melanogenesis in the mouse by topical and
injected melanotropins. J Invest Dermatol 89:269–273, 1987
Levine N, Sheftel SN, Eytan T, et al: Induction of skin tanning by the subcutaneous
administration of a potent synthetic melanotropin. JAMA 266:2730–2736, 1991
Lindberg I: The new eukaryotic precursor processing proteinases. Mol Endocrinol 5:1361–
1365, 1991
Liotta AS, Loudes C, McElvy JM, Krieger DT: Biosynthesis of precursor corticotropin/
endorphin-, corticotropin-, α-melanotropin-, β-lipotropin-, and β-endorphin-like
material by cultured neonatal rat hypothalamic neurons. Proc Natl Acad Sci USA
77:1880–1884, 1980
Lu D, Willard D, Patel IR, et al: Agouti protein is an antagonist of the melanocyte-
stimulating-hormone receptor. Nature 371:799–802, 1994
Luger TA, Scholzen T, Brzoska T, Becher E, Slominski A, Paus R: Cutaneous
immunomodulation and coordination of skin stress responses by α-melanocyte-
stimulating hormone. Ann N Y Acad Sci 840:381–392, 1998
Menon IA, Haberman HF: Mechanisms of action of melanins. Br J Dermatol 97:109–
112, 1977
Menon IA, Persad S, Haberman HF, Kurian CJ: A comparative study of the physical and
chemical properties of melanins isolated from human black and red hair. J Invest
Dermatol 80:202–206, 1983
Menon IA, Persad S, Ranadive NS, Haberman HF. Photobiological effects of eumelanin
and pheomelanin. In: Bagnara JT, Klaus SN, Paul E, Schartl M (eds). Biological
Molecular, Clinical Aspects of Pigmentation. Tokyo: University of Tokyo Press, 1985,
pp. 77–86
Morison WL: What is the function of melanin? Arch Dermatol 121:1160–1163, 1985
Mountjoy KG: The human melanocyte stimulating hormone receptor has evolved to
become ‘super-sensitive’ to melanocortin peptides. Mol Cell Endocrinol 102:R7–
R11, 1994
Mountjoy KG, Robbins LS, Mortrud MT, Cone RD: The cloning of a family of genes
that encode the melanocortin receptors. Science 257:1248–1251, 1992
Murphy MT, Richards DB, Lipton JM: Antipyretic potency of centrally administered α-
melanocyte stimulating hormone. Science 221:192–193, 1983
O’Donohue TL, Dorsa DM: The opiomelanotropinergic neuronal and endocrine systems.
Peptides 3:353–395, 1982
Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS: Interaction of Agouti protein with
the melanocortin 1 receptor in vitro and in vivo. Genes Dev 12:316–330, 1998
Pathak MA: Functions of melanin and protection by melanin. In: Zeise L, Chedekel MR,
Fitzpatrick TB (eds). Melanin: Its Role in Human Photoprotection, Overland Park:
Valdenmar Publishing, 1995, pp. 125–133
Pathak MA, Hori Y, Szabo´ G, Fitzpatrick TB: The photobiology of melanin pigmentation
in human skin. In: Kawamura T, Fitzpatrick TB, Seiji M (eds). Biology of Normal,
Abnormal Melanocytes. Baltimore: University Park Press, 1971, 149–169
Pathak MA, Jimbow K, Fitzpatrick T: Photobiology of pigment cells. In: Seiji M (eds).
Phenotypic Expression in Pigment Cells. Tokyo: University of Tokyo Press, 1980, pp.
655–670
Pawelek JM, Chakraborty AK, Osber MP, Orlow SJ, Min KK, Rosenzweig KE,
Bolognia JL: Molecular cascades in UV-induced melanogenesis: a central role for
melanotropins? Pigment Cell Res 5:348–356, 1992
Pigache RM, Rigter H: Effects of peptides related to ACTH on mood and vigilance in
man. Front Horm Res 8:193–207, 1981
Prota G, Nicolaus RA: On the biogenesis of pheomelanins. In: Montagna W, Hu F (eds).
Advances in Biology of Skin. Vol 8. New York: Pergamon Press, 1967, pp. 323–328
Prota G, D’Ischia M, Napolitano A: The chemistry of melanins and related metabolites.
In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J-P (eds). The Pigmentary
System. Physiology and Pathophysiology. New York: Oxford University Press, 1998,
pp. 307–332
Redman JC: Stratospheric ozone depletion. Am J Dermatopathol 9:457–458, 1987
Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1–6, 1994
Rheins LA, Cotleur AL, Kleier RS, Hoppenjans WB, Sauder DN, Nordlund JJ: Alpha-
melanocyte stimulating hormone modulates contact hypersensitivity responsiveness
in C57BL/6 mice. J Invest Dermatol 93:511–517, 1989
Robbins LS, Nadeau JH, Johnson KR, et al: Pigmentation phenotypes of variant extension
locus alleles result from point mutations that alter MSH receptor function. Cell
72:827–834, 1993
Robertson B, Dostel K, Daynes RA: Neuropeptide regulation of inflammatory and
immunologic responses: The capacity of αmelanocyte stimulating hormone to inhibit
tumor necrosis factor and IL-1-inducible biologic responses. J Immunol 140:4300–
4307, 1988
Roselli-Rehfuss L, Mountjoy KG, Robbins LS, et al: Identification of a receptor for
gamma-melanotropin and other proopiomelanocortin peptides in the hypothalamus
and limbic system. Proc Natl Acad Sci USA 90:8856–8860, 1993
Rubinstein M, Stein S, Undenfriend S: Characterization of pro-opiocortin, a precursor to
opiod peptides and corticotropin. Proc Natl Acad Sci USA 75:669–671, 1978
34 SUZUKI ET AL JID SYMPOSIUM PROCEEDINGS
Sawyer TK, Hruby VJ, Hadley ME, Engel MH: α-Melanocyte stimulating hormone:
Chemical nature and mechanism of action. Am Zool 23:529–540, 1983
Schauer E, Trautinger F, Kock A, et al: Proopiomelanocortin-derived peptides are
synthesized and released by human keratinocytes. J Clin Invest 93:2258–2262, 1994
Seeley RJ, Yagaloff KA, Fisher SL, et al: Melanocortin receptors in leptin effects. Nature
390:349, 1997
Sherbrooke WC, Hadley ME, Castrucci AML: Melanotropic peptides and receptors: an
evolutionary perspective in vertebrate physiologic color change. In: Hadley ME
(eds). Melanotropic Peptides, Vol II. Washington: CRC Press, 1988, pp. 175–190
Silman RE, Street C, Holland D, Chard T, Falconer J, Robinson JS: The pars intermedia
and the fetal pituitary-adrenal axis. Ciba Found Symposium 81:180–190, 1981
Silvers WK: An experimental approach to action of genes at the agouti locus in the mouse.
III. Transplants of newborn Aw-, A-, and at- skin to Ay-, Aw-, A-, and aa hosts. J
Exp Zool 137:189–196, 1958
Silvers WK (ed.): The Coat Colors of Mice. A Model for Mammalian Gene Action and Interaction.
New York: Springer-Verlag, 380 pp, 1979
Smith R, Healy E, Siddiqui S, et al: Melanocortin 1 receptor variants in Irish population.
J Invest Dermatol 111:119–122, 1998
Sober AJ, Lew RA, Koh HK, Barnhill RL: Epidemiology of cutaneous melanoma. An
update. Dermatol Clin 9:617–629, 1991
Suzuki I, Cone R, Im S, Nordlund J, Abdel-Malek Z: Binding capacity and activation of
the MC1 receptors by melanotropic hormones correlate directly with their mitogenic
and melanogenic effects on human melanocytes. Endocrinology 137:1627–1633, 1996
Suzuki I, Tada A, Ollmann MM, et al: Agouti signaling protein inhibits melanogenesis
and the response of human melanocytes to (-melanotropin. J Invest Dermatol 108:838–
842, 1997
Tada A, Suzuki I, Im S, et al: Endothelin-1 is a paracrine growth factor that modulates
melanogenesis of human melanocytes and participates in their responses to ultraviolet
radiation. Cell Growth Differ 9:575–584, 1998
Tamate HB, Takeuchi T: Action of the e locus of mice in the response of phaeomelanic
hair follicles to α-melanocyte-stimulating hormone in vitro. Science 224:1241–
1242, 1984
Thody AJ, Ridley K, Penny RJ, Chalmers R, Fisher C, Shuster S: MSH peptides are
present in mammalian skin. Peptides 4:813–816, 1983
Ullrich SJ, Anderson CW, Mercer WE, Appella E: The p53 tumor suppressor protein, a
modulator of cell proliferation. J Biol Chem 267:15259–15262, 1992
Valverde P, Healy E, Jackson I, Rees JL, Thody AJ: Variants of the melanocyte-stimulating
hormone receptor gene are associated with red hair and fair skin in humans. Nat
Genet 11:328–330, 1995
Valverde P, Healy E, Sikkink S, et al: The Asp84Glu variant of the melanocortin 1 receptor
(MC1R) is associated with melanoma. Hum Mol Genet 5:1663–1666, 1996
Verhaagen J, PM., Edwards FGI, Jennekens P, Schotman, Gispen WH: α-Melanocyte
stimulating hormone stimulates the outgrowth of myelinated nerve fibers after
peripheral nerve crush. Exp Neurol 92:451–454, 1986
Wakamatsu K, Graham A, Cook D, Thody AJ: Characterisation of ACTH peptides in
human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res
10:288–297, 1997
Wong G, Pawelek J, Sansone M, Morowitz J: Response of mouse melanoma cells to
melanocyte stimulating hormone. Nature 248:351–354, 1974
Xu X, Tho¨rnwall M, Lundin L-G, Chhajlani V: Val92Met variant of the melanocyte
stimulating hormone receptor gene. Nat Genet 14:384, 1996
Yang Y, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS, Gantz I: Effects
of recombinant agouti-signalling protein on melanocortin action. Mol Endocrinol
11:274–280, 1997
Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL: Obesity, diabetes, and neoplasia in
yellow Avy/- mice: Ectopic expression of the agouti gene. FASEB J 8:479–488, 1994
